Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Gery Florek

Neurology Tallahassee, FL Medical Doctor

NPI 1205919677 CMS profile 326989

1401 Centerville Rd, Suite 506, Tallahassee, FL 32308

Open in the dashboard

General payments

$66,885

554 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Gery Florek of Tallahassee, FL is reported in the CMS Open Payments database as having received $66,885 across 554 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $70 1
2022 General $231 11
2021 General $36,602 178
2020 General $27,679 211
2019 General $2,303 153

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Gery Florek
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Gery Florek were reported at $0. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Gery Florek Neurology median Middle half National median
2019 $2,303 $474 $118–$2,177 $163
2020 $27,679 $367 $82–$2,309 $114
2021 $36,602 $438 $104–$2,547 $132
2022 $231 $442 $103–$2,388 $149
2023 $0 $464 $119–$2,312 $160
2024 $70 $468 $119–$2,323 $164
2025 $0 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Lilly USA, LLC $22,545 94 payments
  2. AbbVie, Inc. $18,796 50 payments
  3. Allergan Inc. $9,353 46 payments
  4. Amgen Inc. $6,509 48 payments
  5. Biohaven Pharmaceuticals, Inc. $4,471 9 payments
  6. Biogen, Inc. $626 44 payments
  7. Novartis Pharmaceuticals Corporation $500 30 payments
  8. Adamas Pharmaceuticals, Inc. $463 27 payments
  9. Supernus Pharmaceuticals, Inc. $447 44 payments
  10. Upsher-Smith Laboratories LLC $379 23 payments
  11. Other $2,796 139 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $56,765 41 payments
  2. Food and Beverage $8,435 496 payments
  3. Travel and Lodging $1,554 12 payments
  4. Education $90 4 payments
  5. Grant $42 1 payment
Products named General payments · program years 2019–2024
  1. UBRELVY Neuroscience $20,355 37 payments
  2. REYVOW $11,449 27 payments
  3. EMGALITY $9,565 43 payments
  4. UBRELVY Neuroscience $7,338 24 payments
  5. NURTEC ODT $4,471 9 payments
  6. AIMOVIG $4,196 70 payments
  7. GOCOVRI $463 27 payments
  8. TROKENDI XR $384 39 payments
  9. VYEPTI $360 13 payments
  10. TYSABRI $330 27 payments
  11. Other $4,346 255 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

554 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record